Home > Products > API Peptide

  • CAS#130308-48-4
  • NameIcatibant
  • For reserach use only and not for human use!

Product Details

MF： C59H89N19O13S

Appearance： White solid

Cost-effective and customizable Icatibant 130308-48-4 factory

  • Molecular Formula:C59H89N19O13S
  • Molecular Weight:1304.54
  • Appearance/Colour:White solid 
  • Refractive Index:1.742 
  • PKA:3.60±0.21(Predicted) 
  • PSA：544.46000 
  • Density:1.6 g/cm3 
  • LogP:1.58520 

HOE 140(Cas 130308-48-4) Usage

Definition

ChEBI: A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acut attacks of hereditary angioedema in adult patients.

InChI:InChI=1/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38?,39-,40-,41-,42-,43?,44?,45?,46?/m0/s1

130308-48-4 Relevant articles

SYNTHESIS OF ICATIBANT

-

Page/Page column 77, (2019/04/26)

The present invention relates to the eff...

A METHOD FOR PRODUCTION OF HIGH PURITY ICATIBANT

-

Page/Page column 13-16, (2019/11/12)

The present invention provides a process...

Use of bradykinin antagonists for the production of pharmaceuticals for the treatment of chronic fibrogenetic liver disorders and acute liver disorders

-

, (2008/06/13)

This invention relates to a method of tr...

BRADYKININ ANTAGONISTS

-

, (2008/06/13)

-

130308-48-4 Process route

Fmoc-(D)Arg(Pbf)-Arg(Pbf)-Pro-Hyr(tBu)-Gly-OH

Fmoc-(D)Arg(Pbf)-Arg(Pbf)-Pro-Hyr(tBu)-Gly-OH

Fmoc-Ser(tBu)-OH
71989-33-8

Fmoc-Ser(tBu)-OH

N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
130309-33-0

N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid
130309-37-4,1217512-55-4,134526-62-8

1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid

Fmoc-β-(2-thienyl)-L-alanine
130309-35-2,134439-24-0

Fmoc-β-(2-thienyl)-L-alanine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine
187618-60-6

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg
130308-48-4

D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg

Conditions
Conditions Yield
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; With dmap; acetic anhydride; N-ethyl-N,N-diisopropylamine; diisopropyl-carbodiimide; In N,N-dimethyl-formamide; at 20 ℃; for 0.5h;
With piperidine; In N,N-dimethyl-formamide; at 20 ℃;
Fmoc-(D)Arg(Pbf)-Arg(Pbf)-Pro-Hyr(tBu)-Gly-OH; Fmoc-Ser(tBu)-OH; N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid; Fmoc-β-(2-thienyl)-L-alanine; Further stages;
70%
N-(fluoren-9-ylmethoxycarbonyl)glycine
29022-11-5

N-(fluoren-9-ylmethoxycarbonyl)glycine

Fmoc-Pro-OH
71989-31-6

Fmoc-Pro-OH

Fmoc-Ser(tBu)-OH
71989-33-8

Fmoc-Ser(tBu)-OH

(2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid
268729-12-0

(2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid

N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
130309-33-0

N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid
130309-37-4,1217512-55-4,134526-62-8

1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid

Fmoc-β-(2-thienyl)-L-alanine
130309-35-2,134439-24-0

Fmoc-β-(2-thienyl)-L-alanine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine
187618-60-6

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-N<sup>G</sup>-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine
187618-60-6

N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-NG-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine

D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg
130308-48-4

D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg

Conditions
Conditions Yield
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20 ℃;
With methanol; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide;
N-(fluoren-9-ylmethoxycarbonyl)glycine; Fmoc-Pro-OH; Fmoc-Ser(tBu)-OH; (2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid; N-Fmoc-D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; 1‐fluorenylmethoxycarbonyl-(2S,3aS,7aS)‐octahydroindole‐2‐carboxylic acid; Fmoc-β-(2-thienyl)-L-alanine; N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-NG-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine; Reagent/catalyst; Temperature;

130308-48-4 Upstream products

  • 29022-11-5
    29022-11-5

    N-(fluoren-9-ylmethoxycarbonyl)glycine

  • 71989-31-6
    71989-31-6

    Fmoc-Pro-OH

  • 71989-33-8
    71989-33-8

    Fmoc-Ser(tBu)-OH

  • 268729-12-0
    268729-12-0

    (2S,4R)-4-tert-butoxy-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid

Inquiry
Product Name:
Company Name:
*Email:

Please enter your email

Tel:
*Content:

Please enter content

*Code:

Please enter content

The fields marked with*are required

Submit

Related products

  • NameCAS#.